Research Studies
BapineuzumabDescription: Bapineuzumab is a humanized monoclonal antibody, which binds to and clears beta amyloid peptide, and is designed to provide antibodies to beta amyloid directly to the patient. Bapineuzumab is given as a series of injections. This approach is called “passive immunization”
Study Phase: Phase 3
Study Length: 18 months
Study Requirements: Diagnosis of probable AD, Age from 50 to less than 89, and Caregiver or family member able to attend all clinic visits with patient.
Contact: MaryAnn Oakley at 412-692-2721
PiB - Pittsburgh Compound B
Description: This study will use PET imaging to determine how amyloid changes across stages of severity in AD and whether amyloid is present in elderly individuals without memory problems.
Study Length: Varies
Study Requirements: 30 years of age or older, Healthy individuals or Diagnosis of Probable AD, or Diagnosis of MCI
Compensation: Up to $200 per year
Contact: Claire McConaha at 412-692-2727
Other studies
MEG Study
Description: This is a pilot study investigating the use of an imaging technique, called magnetoencephalography (MEG), with Alzheimer's disease (AD). MEG is a completely noninvasive imaging technique that is FDA approved. This study aims to determine how sensitive MEG measures are in identifying early AD. This study will help to determine whether the use of MEG might improve early detection and disease monitoring of AD.
Study Length: 1 to 3 visits lasting 1-2 hours (approx.)
Study Requirements: Diagnosis of AD; 55-88 years; right handed
Contact: MaryAnn Oakley at 412-692-2721
Neural Accumulation Study
Description: This is a functional magnetic resonance imaging (fMRI) study to learn more about neural bases of perceptual decision-making. This study aims to learn more about which areas of the brain are involved in learning, memory and attention.
Study Length: One 60 minute visit (approx.)
Study Requirements: individuals diagnosed with MCI who are 55-85 years of age; right handed
Contact: MaryAnn Oakley at 412-692-2721
Making Sense of MCI: Patient and Family Perspectives
Description: To learn how those diagnosed with mild cognitive impairment (MCI) and their family members make sense of—or come to terms with—their symptoms and diagnosis
Study Length: A one-time interview lasting approximately 45 minutes
Study Requirements: Individuals diagnosed with MCI who have a family member willing to answer questions about them
Contact: MaryAnn Oakley at 412-692-2721